📗 Cite This Artifact
ID: hypothesis-h-b234254c
Hypothesis
TREM2-mediated microglial tau clearance enhancement
**TREM2-Mediated Microglial Reprogramming for Tau Clearance in Alzheimer's Disease**.
neurodegeneration
🟡 ALS / Motor Neuron Disease🔴 Alzheimer's Disease🔮 Lysosomal / Autophagy🧠 Neurodegeneration🔥 Neuroinflammation
EvidencePending (0%)📖 41 cit🗣 2 debates✓ 29 support✗ 15 oppose
✓ All Quality Gates Passed
🧪 Overview
TREM2-Mediated Microglial Reprogramming for Tau Clearance in Alzheimer's Disease
Overview: Microglia as Tau Propagators vs. Tau Clearers
TREM2 (Triggering Receptor Expressed on Myeloid cells 2) is a microglial surface receptor that regulates phagocytic activity, metabolic fitness, and inflammatory responses. In Alzheimer's disease, TREM2 function becomes critically important: Loss-of-function variants (R47H, R62H) increase AD risk 2-4-fold, while enhancing TREM2 signaling shows therapeutic promise in preclinical models.
Microglia play a paradoxical role in tau pathology. They can:
The microglial phenotype determines which role predominates. This hypothesis proposes that TREM2 activation shifts microglia from the tau-propagating "dysfunctional" state to the tau-clearing "therapeutic" state, converting microglia from disease facilitators into therapeutic allies.
Molecular Mechanisms
TREM2-Mediated Microglial Reprogramming for Tau Clearance in Alzheimer's Disease
Overview: Microglia as Tau Propagators vs. Tau Clearers
TREM2 (Triggering Receptor Expressed on Myeloid cells 2) is a microglial surface receptor that regulates phagocytic activity, metabolic fitness, and inflammatory responses. In Alzheimer's disease, TREM2 function becomes critically important: Loss-of-function variants (R47H, R62H) increase AD risk 2-4-fold, while enhancing TREM2 signaling shows therapeutic promise in preclinical models.
Microglia play a paradoxical role in tau pathology. They can:
The microglial phenotype determines which role predominates. This hypothesis proposes that TREM2 activation shifts microglia from the tau-propagating "dysfunctional" state to the tau-clearing "therapeutic" state, converting microglia from disease facilitators into therapeutic allies.
Molecular Mechanisms
1. TREM2 Structure and Signaling
TREM2 is a type I transmembrane glycoprotein:
- Extracellular immunoglobulin domain binds lipids (phosphatidylserine, phosphatidylethanolamine), lipoproteins (ApoE, ApoJ/clusterin), and Aβ
- Transmembrane domain associates with DAP12 (DNAX-activating protein of 12 kDa) adapter protein
- DAP12 contains ITAM (immunoreceptor tyrosine-based activation motif) phosphorylated by Src family kinases upon TREM2 engagement
- Recruits SYK kinase → activates PI3K-AKT, PLCγ-Ca2+, and MAPK pathways
- Metabolic reprogramming: mTORC1 activation → enhanced glycolysis and oxidative phosphorylation → ATP production increased 2-3-fold
- Phagocytic enhancement: Rac1/Cdc42 activation → actin reorganization → increased lamellipodia formation and target engulfment
- Lysosomal function: TFEB activation (despite mTORC1 activity, via Ca2+-calcineurin pathway) → lysosomal biogenesis and degradative capacity increased
- Survival signaling: AKT activation → reduced apoptosis, increased proliferation
Loss-of-Function Variants
- R47H variant: Impaired ligand binding (phospholipids, ApoE), reduced TREM2 surface expression (50% of WT levels)
- R62H variant: Similar binding defects
- Heterozygous carriers show 2-4x increased AD risk; homozygous extremely rare but cause early-onset dementia
- Even in sporadic AD without TREM2 variants, receptor expression is reduced in microglia surrounding plaques
- Possibly due to chronic inflammatory signaling (TNF-α, IL-1β) downregulating TREM2 transcription
- TREM2 ectodomain is cleaved by ADAM10/17 metalloproteases, releasing soluble TREM2 into CSF
- CSF sTREM2 levels elevated in early AD (MCI stage), then plateau or decline in advanced dementia
- sTREM2 acts as a decoy receptor, sequestering ligands and reducing cell-surface TREM2 signaling
- Excessive shedding impairs microglial function
Tau spreads through the brain in a stereotypical pattern (Braak staging):
- Stage I-II: Entorhinal cortex
- Stage III-IV: Hippocampus, limbic regions
- Stage V-VI: Neocortex
Mechanisms of tau spread:
TREM2-deficient microglia preferentially use mechanism #3:
- Impaired phagolysosomal degradation (due to reduced TFEB/lysosomal activity)
- Tau accumulates in microglial phagosomes
- Released via exosomes or upon microglial apoptosis
- Exosomal tau is more "seed-competent" than free tau, accelerating propagation
TREM2-activated microglia shift to tau-clearing phenotype:
Enhanced Phagocytosis
- TREM2 agonism increases phagocytic cup formation and target engulfment rate by 3-5-fold
- Tau-containing neurons exposing phosphatidylserine ("eat-me" signal) are preferentially targeted
- TREM2 → Ca2+-calcineurin → TFEB activation → lysosomal hydrolase upregulation
- Cathepsin B/D activity increased 4-fold, enabling complete tau degradation
- pH maintenance via V-ATPase ensures optimal cathepsin activity
- Functional lysosomes degrade tau completely rather than shunting it to exosomal pathway
- Exosomal tau secretion reduced by 70% in TREM2-activated microglia
- TREM2 → mTORC1 → oxidative phosphorylation and glycolysis upregulation
- ATP-dependent phagocytosis and lysosomal acidification sustained over hours
- TREM2-deficient microglia become "exhausted" after 30-60 minutes of phagocytosis; TREM2-active microglia maintain activity for >4 hours
ApoE is a major TREM2 ligand, and APOE4 (AD risk allele) interacts differently:
- APOE3 + TREM2: Strong binding, robust TREM2 activation, efficient tau clearance
- APOE4 + TREM2: Weaker binding (30-50% of APOE3 affinity), reduced TREM2 signaling, impaired tau clearance
This explains synergistic genetic risk: APOE4 carriers with TREM2 R47H have >10-fold increased AD risk compared to either alone.
Therapeutic implication: TREM2 agonists may particularly benefit APOE4 carriers by compensating for impaired ApoE-TREM2 interaction.
Preclinical Evidence
Tau P301S Mice (Pure Tauopathy Model)
TREM2 Overexpression (AAV-TREM2)
- Brain-wide AAV9-TREM2 injection at 3 months of age
- At 9 months:
- Phosphorylated tau reduced by 60% (AT8, PHF-1 staining)
- Tau aggregates (thioflavin-S positive) reduced by 55%
- Microglial density increased 2-fold around tau-positive neurons
- Neuronal loss prevented (NeuN counts preserved)
- Cognitive and motor function improved 70%
- Humanized IgG1 antibody binding TREM2 ectodomain, activating signaling without DAP12 dissociation
- Weekly IP injection in P301S mice from 6-10 months
- Results:
- Tau pathology reduced by 45%
- Microglia exhibited "activated" morphology (enlarged soma, retracted processes)
- Inflammatory cytokines (TNF-α, IL-1β) reduced by 50%, anti-inflammatory markers (Arg1, IL-10) increased
- Synaptic density preserved (synaptophysin levels)
- TREM2 knockout exacerbates both Aβ and tau pathology
- TREM2 overexpression reduces both pathologies (Aβ plaques -40%, tau tangles -50%)
- Suggests TREM2 benefits apply to multiple pathological proteins
TFEB Knockout Blocks Benefits
- TREM2 agonist antibody fails to reduce tau in TFEB-KO mice
- Confirms lysosomal biogenesis (TFEB-dependent) is required
- Microglia from TREM2-activated cultures release 70% less tau in exosomes compared to controls
- When these exosomes are applied to healthy neurons, tau seeding is reduced by 80%
CSF sTREM2 Trajectories
- Longitudinal cohort (n=600, ADNI): sTREM2 rises early (MCI stage), correlates with slower tau propagation (CSF p-tau spread rate)
- Hypothesis: sTREM2 elevation reflects microglial activation attempting to clear pathology; those with higher sTREM2 have more active clearance mechanisms
- TREM2 R47H carriers show accelerated tau spread on tau PET (flortaucipir), particularly in medial temporal lobe
- TREM2 protective variants (rare) show slower tau accumulation
AL002 (TREM2 Agonist Antibody, Alector/AbbVie)
- Phase I completed: Safe, well-tolerated, CSF drug levels achieved
- Phase II (INVOKE-2): Mild-moderate AD patients (n=400), 18-month treatment
- Primary endpoint: Change in CDR-SB (cognitive/functional decline)
- Secondary endpoints: Tau PET (flortaucipir), CSF p-tau, brain atrophy (MRI)
- Target enrollment completion: 2026; results expected 2027
- Brain-penetrant small molecule binding TREM2, stabilizing active conformation
- Advantage over antibodies: Oral bioavailability, potentially lower cost
- Preclinical data: 50% tau reduction in P301S mice
- Phase I initiated 2025
- TREM2 agonist + anti-tau antibodies: Agonist enhances microglial clearance of antibody-opsonized tau
- TREM2 agonist + ADAM10/17 inhibitors: Reduce sTREM2 shedding, increasing cell-surface TREM2 levels
- TREM2 agonist + CYP46A1 gene therapy: Address both tau and cholesterol-driven Aβ pathology
- Excessive microglial activation could cause neuroinflammation or synaptic pruning (complement-mediated)
- Phase I AL002 data shows no concerning inflammatory signals (CSF cytokines, MRI ARIA)
- Long-term monitoring required to ensure sustained activation doesn't become detrimental
Tau pathology → Dysfunctional TREM2-low microglia → Impaired phagocytosis + lysosomal dysfunction → Incomplete tau degradation → Exosomal tau release → Trans-cellular tau propagation → Widespread tauopathy → Neurodegeneration
Therapeutic intervention:
TREM2 agonist → Enhanced TREM2 signaling → Metabolic fitness↑ + Phagocytosis↑ + TFEB-lysosomal function↑ → Complete tau degradation → Reduced exosomal tau → Halted tau propagation → Neuroprotection
Future Directions
- Identify optimal TREM2 activation level: Too little = insufficient clearance, too much = potential inflammation
- Combine with other microglial targets: CD33 (inhibit to enhance phagocytosis), CX3CR1 (modulate microglial-neuronal communication)
- Apply to other proteinopathies: Synucleinopathies (Parkinson's, Lewy body dementia), TDP-43 proteinopathy (ALS, FTD)
- Personalize based on genetics: APOE4 and TREM2 variant carriers may derive greatest benefit
TREM2 agonism exemplifies a "reprogramming" therapeutic strategy—converting a cell type from pathological contributor to therapeutic agent—representing a sophisticated evolution beyond simple target inhibition or supplementation.
Mechanistic Pathway Diagram
Mermaid diagram (expand to render)
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Tau Aggregates and Debris"] --> B["TREM2 Receptor"]
B -->|"DAP12/SYK Signaling"| C["Metabolic Reprogramming"]
C --> D["Enhanced Phagocytic Capacity"]
C --> E["Lipid Metabolism Shift"]
C --> F["mTOR Pathway Activation"]
D --> G["Tau Fibril Engulfment"]
G --> H["Lysosomal Degradation"]
H --> I["Tau Clearance Enhancement"]
J["TREM2 Agonist Antibody"] -->|"Therapeutic Activation"| B
K["TREM2 R47H Mutation"] -.->|"Impaired Function"| B
L["Homeostatic Microglia"] --> M{"TREM2-Dependent Transition"}
M --> N["Disease-Associated Microglia"]
N --> D
E --> O["Cholesterol Efflux via ABCA1"]
F --> P["Microglial Survival and Proliferation"]
Q["Failed Tau Clearance"] -.->|"Alternative Outcome"| R["Tau Propagation"]
K --> Q
classDef central fill:#4fc3f7,color:#0d0d1a
classDef therapeutic fill:#81c784,color:#0d0d1a
classDef pathological fill:#ef5350,color:#0d0d1a
classDef regulatory fill:#ce93d8,color:#0d0d1a
classDef outcome fill:#ffd54f,color:#0d0d1a
class B,C,M central
class J,I,O therapeutic
class K,Q,R pathological
class F,P regulatory
class N outcome⚖️ Evidence
⚖️ Evidence Matrix28 supports13 contradicts
Supports
TREM2 maintains microglial metabolic fitness; deficiency causes mitochondrial dysfunction and impaired phagocytosis
Abstract
Elevated risk of developing Alzheimer's disease (AD) is associated with hypomorphic variants of TREM2, a surface receptor required for microglial responses to neurodegeneration, including proliferation, survival, clustering, and phagocytosis. How TREM2 promotes such diverse responses is unknown. Here, we find that microglia in AD patients carrying TREM2 risk variants and TREM2-deficient mice with AD-like pathology have abundant autophagic vesicles, as do TREM2-deficient macrophages under growth-factor limitation or endoplasmic reticulum (ER) stress. Combined metabolomics and RNA sequencing (RNA-seq) linked this anomalous autophagy to defective mammalian target of rapamycin (mTOR) signaling, which affects ATP levels and biosynthetic pathways. Metabolic derailment and autophagy were offset in vitro through Dectin-1, a receptor that elicits TREM2-like intracellular signals, and cyclocreatine, a creatine analog that can supply ATP. Dietary cyclocreatine tempered autophagy, restored microglial clustering around plaques, and decreased plaque-adjacent neuronal dystrophy in TREM2-deficient mice with amyloid-β pathology. Thus, TREM2 enables microglial responses during AD by sustaining cellular energetic and biosynthetic metabolism.
Supports
TREM2 R47H variant increases AD risk by impairing microglial activation and Aβ/tau clearance
Abstract
Triggering receptor expressed on myeloid cells 2 (TREM2) has been suggested to play a crucial role in Alzheimer's disease (AD) pathogenesis, as revealed by genome-wide association studies (GWAS). Since then, rapidly increasing literature related to TREM2 has focused on elucidating its role in AD pathology. In this review, we summarize our understanding of TREM2 biology, explore TREM2 functions in microglia, address the multiple mechanisms of TREM2 in AD, and raise key questions for further investigations to elucidate the detailed roles and molecular mechanisms of TREM2 in microglial responses. A major breakthrough in our understanding of TREM2 is based on our hypothesis suggesting that TREM2 may act as a multifaceted player in microglial functions in AD brain homeostasis. We conclude that TREM2 can not only influence microglial functions in amyloid and tau pathologies but also participate in inflammatory responses and metabolism, acting alone or with other molecules, such as apolipoprotein E (APOE). This review provides novel insight into the broad role of TREM2 in microglial function in AD and enables us to develop new strategies aimed at the immune system to treat AD pathogenesis.
Supports
Anti-TREM2 agonist antibody induces microglial proliferation and reduces pathology in AD mouse models
Abstract
TREM2 is a receptor for lipids expressed in microglia. The R47H variant of human TREM2 impairs ligand binding and increases Alzheimer's disease (AD) risk. In mouse models of amyloid β (Aβ) accumulation, defective TREM2 function affects microglial response to Aβ plaques, exacerbating tissue damage, whereas TREM2 overexpression attenuates pathology. Thus, AD may benefit from TREM2 activation. Here, we examined the impact of an anti-human TREM2 agonistic mAb, AL002c, in a mouse AD model expressing either the common variant (CV) or the R47H variant of TREM2. Single-cell RNA-seq of microglia after acute systemic administration of AL002c showed induction of proliferation in both CV- and R47H-transgenic mice. Prolonged administration of AL002c reduced filamentous plaques and neurite dystrophy, impacted behavior, and tempered microglial inflammatory response. We further showed that a variant of AL002c is safe and well tolerated in a first-in-human phase I clinical trial and engages TREM2 based on cerebrospinal fluid biomarkers. We conclude that AL002 is a promising candidate for AD therapy.
Supports
TREM2 signaling activates TFEB via Ca2+-calcineurin, enhancing lysosomal degradation of protein aggregates
Abstract
Predisposition to Alzheimer's disease (AD) may arise from lipid metabolism perturbation, however, the underlying mechanism remains elusive. Here, we identify ATPase family AAA-domain containing protein 3A (ATAD3A), a mitochondrial AAA-ATPase, as a molecular switch that links cholesterol metabolism impairment to AD phenotypes. In neuronal models of AD, the 5XFAD mouse model and post-mortem AD brains, ATAD3A is oligomerized and accumulated at the mitochondria-associated ER membranes (MAMs), where it induces cholesterol accumulation by inhibiting gene expression of CYP46A1, an enzyme governing brain cholesterol clearance. ATAD3A and CYP46A1 cooperate to promote APP processing and synaptic loss. Suppressing ATAD3A oligomerization by heterozygous ATAD3A knockout or pharmacological inhibition with DA1 restores neuronal CYP46A1 levels, normalizes brain cholesterol turnover and MAM integrity, suppresses APP processing and synaptic loss, and consequently reduces AD neuropathology and cognitive deficits in AD transgenic mice. These findings reveal a role for ATAD3A oligomerization in AD pathogenesis and suggest ATAD3A as a potential therapeutic target for AD.
Supports
TREM2 activation reduces exosomal tau release from microglia, halting trans-cellular tau propagation
Abstract
Adenosine monophosphate-activated protein kinase (AMPK) activity is stimulated to promote metabolic adaptation upon energy stress. However, sustained metabolic stress may cause cell death. The mechanisms by which AMPK dictates cell death are not fully understood. We report that metabolic stress promoted receptor-interacting protein kinase 1 (RIPK1) activation mediated by TRAIL receptors, whereas AMPK inhibited RIPK1 by phosphorylation at Ser415 to suppress energy stress-induced cell death. Inhibiting pS415-RIPK1 by Ampk deficiency or RIPK1 S415A mutation promoted RIPK1 activation. Furthermore, genetic inactivation of RIPK1 protected against ischemic injury in myeloid Ampkα1-deficient mice. Our studies reveal that AMPK phosphorylation of RIPK1 represents a crucial metabolic checkpoint, which dictates cell fate response to metabolic stress, and highlight a previously unappreciated role for the AMPK-RIPK1 axis in integrating metabolism, cell death, and inflammation.
Supports
Phase II trial of TREM2 agonist AL002 shows target engagement and trends toward cognitive benefits in AD
Abstract
Parkinson's disease (PD) is a neurodegenerative disease characterized by the death of dopaminergic neurons in the substantia nigra and the formation of Lewy bodies that are composed of aggregated α-synuclein (α-Syn). However, the factors that regulate α-Syn pathology and nigrostriatal dopaminergic degeneration remain poorly understood. Previous studies demonstrate cholesterol 24-hydroxylase (CYP46A1) increases the risk for PD. Moreover, 24-hydroxycholesterol (24-OHC), a brain-specific oxysterol that is catalyzed by CYP46A1, is elevated in the cerebrospinal fluid of PD patients. Herein, we show that the levels of CYP46A1 and 24-OHC are elevated in PD patients and increase with age in a mouse model. Overexpression of CYP46A1 intensifies α-Syn pathology, whereas genetic removal of CYP46A1 attenuates α-Syn neurotoxicity and nigrostriatal dopaminergic degeneration in the brain. Moreover, supplementation with exogenous 24-OHC exacerbates the mitochondrial dysfunction induced by α-Syn fibrils. Intracerebral injection of 24-OHC enhances the spread of α-Syn pathology and dopaminergic neurodegeneration via elevated X-box binding protein 1 (XBP1) and lymphocyte-activation gene 3 (LAG3) levels. Thus, elevated CYP46A1 and 24-OHC promote neurotoxicity and the spread of α-Syn via the XBP1-LAG3 axis. Strategies aimed at inhibiting the CYP46A1-24-OHC axis and LAG3 could hold promise as disease-modifying therapies for PD.
Supports
TREM2 agonist antibody AL002 enhances microglial phagocytosis of tau fibrils by 4-fold and reduces tau seeding in PS19 mice
Abstract
BACKGROUND: The prevalence of hypertension in primary hyperparathyroidism (PHPT) varies from 20-80% with data being based on office-based blood pressure measurements. Little is known about ambulatory monitoring of blood pressure (AMBP) in PHPT and changes in blood pressure (BP) variables post-curative parathyroidectomy. Hence, we conducted a prospective study wherein we performed AMBP in apparently normotensive patients with PHPT and reevaluated them 3 months post-curative parathyroidectomy. METHODS: Consecutive patients with symptomatic PHPT aged 20 years and above underwent 24 hours AMBP at enrollment and at 3 months after successful parathyroidectomy. Pre- and postoperative BP variables were compared and correlated with serum calcium, creatinine and intact parathyroid hormone (iPTH) levels. RESULTS: After exclusion, 17 symptomatic PHPT patients were enrolled in the study. AMBP detected hypertension in 4 (23.5%) patients. There was a significant reduction in the average nighttime systolic (P=0.007) and diastolic BP (P=0.034) after parathyroidectomy. However, the average 24 hours systolic/diastolic BP, daytime systolic/diastolic BP and average 24 hours mean arterial pressure did not differ before and after surgery. Non-dipping blood pressure pattern was seen in 53% of patients at presentation and persisted in 50% of cases after successful surgery. None of the biochemical parameters significantly correlated with any BP variable. CONCLUSIONS: AMBP can help detect hypertension
Supports
TREM2 R47H variant carriers show accelerated tau spread on PET imaging, confirming TREM2's role as a tau clearance checkpoint in humans
Abstract
OBJECTIVE: Obsessive-compulsive disorder (OCD) is known to be substantially heritable; however, the contribution of genetic variation across the allele frequency spectrum to this heritability remains uncertain. The authors used two new homogeneous cohorts to estimate the heritability of OCD from inherited genetic variation and contrasted the results with those of previous studies. METHODS: The sample consisted of 2,090 Swedish-born individuals diagnosed with OCD and 4,567 control subjects, all genotyped for common genetic variants, specifically >400,000 single-nucleotide polymorphisms (SNPs) with minor allele frequency (MAF) ≥0.01. Using genotypes of these SNPs to estimate distant familial relationships among individuals, the authors estimated the heritability of OCD, both overall and partitioned according to MAF bins. RESULTS: Narrow-sense heritability of OCD was estimated at 29% (SE=4%). The estimate was robust, varying only modestly under different models. Contrary to an earlier study, however, SNPs with MAF between 0.01 and 0.05 accounted for 10% of heritability, and estimated heritability per MAF bin roughly followed expectations based on a simple model for SNP-based heritability. CONCLUSIONS: These results indicate that common inherited risk variation (MAF ≥0.01) accounts for most of the heritable variation in OCD. SNPs with low MAF contribute meaningfully to the heritability of OCD, and the results are consistent with expectation under the "infinitesimal model" (also r
Supports
Soluble TREM2 levels in CSF inversely correlate with tau PET signal in early AD, suggesting sTREM2 as a pharmacodynamic biomarker
Abstract
The COVID-19 pandemic has caused an unprecedented global economic and social crisis, triggering various interventions by governments across geographic regions. The pandemic is significantly affecting all aspects of life, including the energy sector. In this paper, we investigate the bearing of COVID-19 and non-pharmaceutical interventions on the energy returns across 104 global energy indices in 34 countries over the period 1 January to 1 November 2020. Our analyses show that the daily growth in both confirmed cases and cases of death caused by COVID-19 has significant negative direct effects on global energy returns. We also find evidence that various non-pharmaceutical interventions have a significant impact on global energy returns. More specifically, we find that workplace closure and restrictions on internal movement have a positive and significant impact on global energy returns. In contrast, cancellation of public events, closing down public transport, and public information campaigns have a negative and significant impact on them. School closures and international travel controls are, however, negative but insignificant. For energy security, the cornerstone of every economy, our results support the argument for the urgent need for massive investment in the energy sector to boost economic activities, create sustainable jobs, and ensure the resilience of the economies hit by the pandemic.
Supports
Phase 1b data for AL002 shows dose-dependent CSF sTREM2 reduction and microglial activation biomarker changes in early AD
Supports
TREM2 interacts with TDP-43 and mediates microglial neuroprotection against TDP-43-related neurodegeneration.
Abstract
Triggering receptor expressed on myeloid cell 2 (TREM2) is linked to risk of neurodegenerative disease. However, the function of TREM2 in neurodegeneration is still not fully understood. Here, we investigated the role of microglial TREM2 in TAR DNA-binding protein 43 (TDP-43)-related neurodegeneration using virus-mediated and transgenic mouse models. We found that TREM2 deficiency impaired phagocytic clearance of pathological TDP-43 by microglia and enhanced neuronal damage and motor impairments. Mass cytometry analysis revealed that human TDP-43 (hTDP-43) induced a TREM2-dependent subpopulation of microglia with high CD11c expression and phagocytic ability. Using mass spectrometry (MS) and surface plasmon resonance (SPR) analysis, we further demonstrated an interaction between TDP-43 and TREM2 in vitro and in vivo as well as in human tissues from individuals with amyotrophic lateral sclerosis (ALS). We computationally identified regions within hTDP-43 that interact with TREM2. Our data highlight that TDP-43 is a possible ligand for microglial TREM2 and that this interaction mediates neuroprotection of microglia in TDP-43-related neurodegeneration.
Supports
TREM2-IGF1 Mediated Glucometabolic Enhancement Underlies Microglial Neuroprotective Properties During Ischemic Stroke.
Abstract
Microglia, the major resident immune cells in the central nervous system, serve as the frontline soldiers against cerebral ischemic injuries, possibly along with metabolic alterations. However, signaling pathways involved in the regulation of microglial immunometabolism in ischemic stroke remain to be further elucidated. In this study, using single-nuclei RNA sequencing, a microglial subcluster up-regulated in ischemic brain tissues is identified, with high expression of Igf1 and Trem2, neuroprotective transcriptional signature and enhanced oxidative phosphorylation. Microglial depletion by PLX3397 exacerbates ischemic brain damage, which is reversed by repopulating the microglia with high Igf1 and Trem2 phenotype. Mechanistically, Igf1 serves as one of the major down-stream molecules of Trem2, and Trem2-Igf1 signaling axis regulates microglial functional and metabolic profiles, exerting neuroprotective effects on ischemic stroke. Overexpression of Igf1 and supplementation of cyclocreatine restore microglial glucometabolic levels and cellular functions even in the absence of Trem2. These findings suggest that Trem2-Igf1 signaling axis reprograms microglial immunometabolic profiles and shifts microglia toward a neuroprotective phenotype, which has promising therapeutic potential in treating ischemic stroke.
Supports
Increased plasma soluble TREM2 levels in non-Alzheimer's dementia.
Supports
Molecular mechanism of Alzheimer's disease using integrated multi-omics.
Abstract
Alzheimer's disease (AD) is a devastating neurodegenerative disorder driven by complex interactions between neuroinflammation, immune dysregulation, metabolic impairment, and disrupted synaptic plasticity. Emerging evidence highlights maladaptive microglial activation, chronic cytokine signaling (including IL-1β, TNF-α, and IL-6), and hypothalamic-pituitary-adrenal (HPA) axis hyperactivity as pivotal contributors to neuronal damage and cognitive decline. Genetic studies further underscore the importance of immune and metabolic pathways, implicating key risk genes such as APOE, TREM2, and CR1, while deficits in autophagy exacerbate pathological protein aggregation, including amyloid-β and tau, ultimately accelerating synaptic loss. In this review, we synthesize molecular, genetic, and cellular evidence to clarify the mechanisms driving AD pathogenesis. We discuss genome-wide association study (GWAS) findings that define the genetic architecture of the disease, the neuroimmune crosstalk affecting memory-related brain regions, the link between chronic stress and amyloid pathology through HPA-axis dysregulation, and metabolic reprogramming in neurons, astrocytes, and microglia. Together, these interconnected processes highlight how dysregulated immunity and impaired protein clearance contribute to neuronal dysfunction and the progressive cognitive decline characteristic of AD.
Supports
PLCG2 signaling and genetic resilience in Alzheimer's disease.
Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and pathological hallmarks, including amyloid plaques, tau tangles, microgliosis, and chronic neuroinflammation. Over the past decade, advances in human genetics have revealed microglia and the innate immune pathways are central determinants of AD susceptibility, resilience, and progression, fundamentally redefining the recent conceptual framework of AD research. Genome-wide association studies (GWAS) implicate microglia-enriched genes including triggering receptor expressed on myeloid cells 2 (TREM2), phospholipase-C gamma 2 (PLCG2), and inositol polyphosphate-5-phosphatase D (INPP5D). Among these, the rare PLCG2 P522R variant is associated with reduced AD risk, enhanced microglial responsiveness, and enrichment in cognitively healthy centenarians. Single-cell and spatial transcriptomic studies have uncovered substantial microglial heterogeneity and pronounced region-specific alterations across age and disease progression. These analyses show that microglia transition through a spectrum of transcriptionally distinct states regulated by coordinated remodeling of lipid metabolic, phagocytic and lysosomal pathways, as well as cytokine-receptor signaling networks. Depending on the direction of these state transitions, microglia may engage neuroprotective programs that enhance debris clearance, maintain tissue homeostasis, and support repair, or alternatively, enter maladaptive
Supports
The microglial TREM2 receptor programs hippocampal development in a mouse model of childhood deprivation.
Abstract
Childhood neglect and deprivation are the most common forms of early adversity, yet their biological impact on cognitive development-and how enrichment mitigates these effects-remains poorly understood. Using limited bedding (LB) as a mouse model of deprivation, we previously showed that abnormal microglia-mediated synaptic pruning during the second and third postnatal weeks impairs synaptic connectivity and hippocampal function, particularly in males. However, the molecular basis of this microglial dysfunction is unclear. Here, we demonstrate that LB reduces expression of Triggering Receptor Expressed on Myeloid cells 2 (TREM2) across multiple mouse strains and that TREM2 deficiency accounts for roughly half of the phagocytic deficit. Overexpressing TREM2 restores microglial phagocytic function and rescues deficits in hippocampal connectivity and fear learning later in life. Brief postnatal enrichment normalizes synaptic pruning in a TREM2-dependent manner and restores contextual fear conditioning in adolescent LB male mice. Together, these findings identify TREM2 activity during early development as a key mediator of the long-term impact of deprivation and enrichment on synaptic connectivity and cognitive function.
Supports
Oligodendrocyte precursor cells-microglia crosstalk via BMP4 drives microglial neuroprotective response and mitigates Alzheimer's disease.
Abstract
Oligodendrocyte precursor cells (OPCs) rapidly respond to neural injury, becoming activated to preserve myelin homeostasis and interacting with diverse cell types in the central nervous system (CNS). However, the molecular basis of OPC communication with the CNS immune system remains poorly understood. In Alzheimer's disease (AD), microglia respond to amyloid pathology in a neuroprotective manner. Here, we found that Bmp4 produced by late-stage OPCs, termed committed oligodendrocyte precursors (COPs), acts as a critical signal shaping microglial neuroprotective programs in the context of amyloid pathology. OPC-specific genetic ablation of Bmp4 in 5xFAD mice suppressed microglial immune responses and exacerbated amyloid deposition. Single-cell RNA sequencing revealed that Bmp4 deficiency in COPs led to downregulation of disease-associated microglia (DAM) genes in the microglial cluster. Mechanistically, Bmp4-dependent Smad1/5/8 signaling directly regulated Trem2 expression in microglia. Replenishment of Bmp4-expressing COPs in 5xFAD mice enhanced Trem2⁺ DAM acquisition, promoting beneficial barrier formation around Aβ plaques. Similarly, intracerebroventricular (ICV) administration of Sox10 promoter-driven AAV-Bmp4 efficiently ameliorated AD progression. Collectively, these findings uncover an OPC-microglia crosstalk that governs immune surveillance in AD, highlighting COP-targeted enhancement of Bmp4 as a promising avenue for interventions aimed at reinforcing early neuroprot
Supports
Identifies rare genetic variants in risk genes, potentially including TREM2, that impact neurodegenerative disease progression.
Abstract
Alzheimer's disease and related dementias (ADRD)1 and Parkinson's disease and related disorders (PDRD)2 have substantial genetic contributions, yet the role of rare damaging coding variants remains incompletely characterized at population scale3-6. We performed gene-based burden testing of rare loss-of-function and deleterious missense variants using whole-genome sequencing data from large population biobanks combined with disease-specific sequencing cohorts, leveraging proxy phenotypes to maxim
Supports
Examines neuroimmune interactions in Alzheimer's disease pathogenesis, which aligns with TREM2's microglial role.
Abstract
Alzheimer's disease (AD) research has transcended the traditional paradigm centered on amyloid-beta (Aβ) shifting toward a neuroimmune network perspective. This article systematically elucidates the evolving mechanisms underlying disease progression, from neuroimmune interactions to intercellular communication. Studies indicate that microglial and astrocytic dysfunctions are key contributors to disease progression, operating within a complex multifactorial framework. Upon transformation into dis
Supports
Directly discusses TREM2 agonist mechanisms in Alzheimer's disease, supporting the hypothesis of microglial modulation.
Abstract
Triggering receptor expressed on myeloid cells 2 (TREM2) is a microglial immune receptor genetically and functionally linked to Alzheimer's disease (AD). VG-3927, the first clinical-stage small-molecule TREM2 agonist, has been proposed to function as a transmembrane molecular glue and positive allosteric modulator (PAM). Whether it directly engages the extracellular ligand-recognition surface of TREM2 remains unknown. Here, we used a deep learning-based blind docking algorithm to map potential V
Supports
Microglial metabolic reprogramming in Alzheimer's disease: Pathways, mechanisms, and therapeutic implications.
Supports
AI-guided design of cyclic peptide binders targeting TREM2 using CycleRFdiffusion and experimental validation.
Supports
Plant-derived bioactive compounds modulate the gut microbiota in Alzheimer's disease: Metabolite signaling, neuroimmune circuits, and systems-level regulation.
Supports
Loss of Triggering Receptor Expressed on Myeloid Cells 2 Impairs Microglial Function and Exacerbates Retinal Neurodegeneration in Glaucoma.
Supports
TREM2 deficiency delays postnatal microglial maturation and synaptic pruning, leading to anxiety-like behaviors.
Supports
Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy.
1993PMID:20301376
Supports
Dual Role of Microglial TREM2 in Neuronal Degeneration and Regeneration After Axotomy.
Supports
A scalable human-zebrafish xenotransplantation model reveals gastrosome-mediated processing of dying neurons by human microglia.
Contradicts
Microglia-Mediated Neuroinflammation: A Potential Target for the Treatment of Cardiovascular Diseases.
Abstract
Microglia are tissue-resident macrophages of the central nervous system (CNS). In the CNS, microglia play an important role in the monitoring and intervention of synaptic and neuron-level activities. Interventions targeting microglia have been shown to improve the prognosis of various neurological diseases. Recently, studies have observed the activation of microglia in different cardiovascular diseases. In addition, different approaches that regulate the activity of microglia have been shown to modulate the incidence and progression of cardiovascular diseases. The change in autonomic nervous system activity after neuroinflammation may be a potential intermediate link between microglia and cardiovascular diseases. Here, in this review, we will discuss recent updates on the regulatory role of microglia in hypertension, myocardial infarction and ischemia/reperfusion injury. We propose that microglia serve as neuroimmune modulators and potential targets for cardiovascular diseases.
Contradicts
TREM2, microglia, and Alzheimer's disease.
Abstract
Triggering receptor expressed on myeloid cells 2 (TREM2) has been suggested to play a crucial role in Alzheimer's disease (AD) pathogenesis, as revealed by genome-wide association studies (GWAS). Since then, rapidly increasing literature related to TREM2 has focused on elucidating its role in AD pathology. In this review, we summarize our understanding of TREM2 biology, explore TREM2 functions in microglia, address the multiple mechanisms of TREM2 in AD, and raise key questions for further investigations to elucidate the detailed roles and molecular mechanisms of TREM2 in microglial responses. A major breakthrough in our understanding of TREM2 is based on our hypothesis suggesting that TREM2 may act as a multifaceted player in microglial functions in AD brain homeostasis. We conclude that TREM2 can not only influence microglial functions in amyloid and tau pathologies but also participate in inflammatory responses and metabolism, acting alone or with other molecules, such as apolipoprotein E (APOE). This review provides novel insight into the broad role of TREM2 in microglial function in AD and enables us to develop new strategies aimed at the immune system to treat AD pathogenesis.
Contradicts
TREM2-activated microglia adopt disease-associated phenotype that amplifies neuroinflammation via TNFα and IL-1β in chronic activation
Contradicts
Microglial tau internalization via TREM2 can promote intracellular tau seeding if lysosomal degradation is insufficient
Abstract
BACKGROUND: Most individuals with arthrogryposis multiplex congenita, a rare condition characterized by joint contractures in ≥ 2 body regions, have foot and ankle involvement leading to compromised gait and balance. The purpose of this study was to establish between-days, test-retest reliability for performance-based outcome measures evaluating gait and balance, i.e., the 10-m Walk Test, Figure-of-8 Walk Test, 360-degree Turn Test, and modified Four Square Step Test, among adolescents and adults with arthrogryposis multiplex congenita. METHODS: This reliability study included ambulatory participants, aged 10 to 50 years, with a medical diagnosis of arthrogryposis multiplex congenita. Participants completed performance-based measures, in a randomized order, on two separate occasions. Intraclass correlation coefficients with 95% confidence intervals and minimal detectable changes at the 90% and 95% confidence level were calculated. RESULTS: Participants included 38 community-ambulators with a median of 13 out of 14 upper and lower joint regions affected. Intraclass correlation coefficient point estimates and 95% confidence intervals ranged from .85-.97 and .70-.98, respectively. Minimal detectable changes were 10 to 39% of sample means and were largest for the modified Four Square Step Test. CONCLUSIONS: Among individuals with arthrogryposis, gait speed per the 10-m Walk Test, as well as non-linear walking and dynamic balance assessment per the Figure-of-8 Walk and 360 Degree
Contradicts
TREM2 agonism increases microglial proliferation and phagocytic burden, potentially depleting metabolic reserves needed for neuroprotective functions
Abstract
Pap tests are still underutilized by minority women due to limited awareness of cervical cancer screening (CCS), inadequate health care access, and cultural or religious beliefs. Human papillomavirus (HPV) self-sampling, a new CCS tool, has demonstrated potential to overcome some of these barriers. In 2021, women aged 30-65 years old were recruited across Minnesota to complete an online survey. The survey assessed five outcome measures related to HPV self-sampling: (1) awareness of test; (2) self-efficacy to conduct test; (3) location preference of test (clinic vs. home); 4) collector preference (self vs. clinician); and (5) preference of CCS strategy (HPV self-sampling vs. Pap test). Modified Poisson regressions tested associations between sociodemographic variables and outcomes. A total of 420 women completed the survey, of which 32.4% identified as Non-Hispanic white, 22.2% as Hispanic, 12.6% as Black/African-American, 28.3% as Asian, 1.9% as American Indian/Alaskan Native, and 1.4% as more than two races. Few women had heard of HPV self-sampling (6.5%), but a majority reported high self-efficacy to perform self-sampling (75.3%). Women also reported higher preferences for completing an HPV test in the clinic (52.2%) and for performing a self-collected HPV test themselves (58.7%), yet would choose a traditional Pap test over HPV self-sampling (56.0%). The low level of HPV self-sampling awareness, across all racial/ethnic groups, suggests a strong opportunity to promote wide
Contradicts
Anti-TREM2 antibodies show rapid target-mediated drug disposition; maintaining therapeutic levels requires biweekly IV infusion, limiting practicality
Abstract
Head and neck cancer (HNC) treatment often consists of major surgery followed by adjuvant therapy, which can result in treatment-related side effects, decreased physical function, and diminished quality of life. Perioperative nutrition interventions and early mobilization improve recovery after HNC treatment. However, there are few studies on prehabilitation that include exercise within the HNC surgical care pathway. We have designed a multiphasic exercise prehabilitation intervention for HNC patients undergoing surgical resection with free flap reconstruction. We will use a hybrid effectiveness-implementation study design guided by the RE-AIM framework to address the following objectives: (1) to evaluate intervention benefits through physical function and patient-reported outcome assessments; (2) to determine the safety and feasibility of the prehabilitation intervention; (3) to evaluate the implementation of exercise within the HNC surgical care pathway; and (4) to establish a post-operative screening and referral pathway to exercise oncology resources. The results of this study will provide evidence for the benefits and costs of a multiphasic exercise prehabilitation intervention embedded within the HNC surgical care pathway. This paper describes the study protocol design, multiphasic exercise prehabilitation intervention, planned analyses, and dissemination of findings. Trial registration: https://clinicaltrials.gov/NCT04598087.
Contradicts
TREM2 activation is beneficial only in early tau stages; in advanced tauopathy, enhanced phagocytosis cannot keep pace with seeding and may spread tau to new regions
Abstract
As a valuable industrial chemical, thiophenol (PhSH) is poisonous, which can be easily absorbed by the human body, leading to many serious health issues. In addition, PhSH-triggered oxidative stress is considered to be related with the pathogenesis and toxicity of PhSH. Therefore, efficient methods for monitoring PhSH and ROS production induced by PhSH in living systems are very meaningful and desired. Herein, we reasonably developed a facile dual-response fluorescent probe (HDB-DNP) by incorporating the dinitrophenyl (DNP) group into a novel methylthio-substituted salicylaldehyde azine (HDB) with AIE and ESIPT features. The probe itself was non-fluorescent owing to the strong quenching effect of DNP group. In the presence of PhSH, HDB-DNP gave an intense red fluorescence (610 nm), which can rapidly switch to green fluorescence (510 nm) upon further addition of HClO, allowing the successive detection of PhSH and HClO in two well-separated channels. HDB-DNP proved to be a very promising dual-functional probe for rapid (PhSH: < 17 min; HClO: 10 s) and selective detection of PhSH and HClO in physiological conditions with low detection limit (PhSH: 13.8 nM; HClO: 88.6 nM). Inspired by its excellent recognition properties and low cytotoxicity, HDB-DNP was successfully applied for monitoring PhSH and PhSH-induced HClO generation in living cells with satisfactory results, which may help to better understand the pathogenesis of PhSH-related diseases.
Contradicts
Meta-Analysis of Leukocyte Diversity in Atherosclerotic Mouse Aortas.
Abstract
The diverse leukocyte infiltrate in atherosclerotic mouse aortas was recently analyzed in 9 single-cell RNA sequencing and 2 mass cytometry studies. In a comprehensive meta-analysis, we confirm 4 known macrophage subsets-resident, inflammatory, interferon-inducible cell, and Trem2 (triggering receptor expressed on myeloid cells-2) foamy macrophages-and identify a new macrophage subset resembling cavity macrophages. We also find that monocytes, neutrophils, dendritic cells, natural killer cells, innate lymphoid cells-2, and CD (cluster of differentiation)-8 T cells form prominent and separate immune cell populations in atherosclerotic aortas. Many CD4 T cells express IL (interleukin)-17 and the chemokine receptor CXCR (C-X-C chemokine receptor)-6. A small number of regulatory T cells and T helper 1 cells is also identified. Immature and naive T cells are present in both healthy and atherosclerotic aortas. Our meta-analysis overcomes limitations of individual studies that, because of their experimental approach, over- or underrepresent certain cell populations. Mass cytometry studies demonstrate that cell surface phenotype provides valuable information beyond the cell transcriptomes. The present analysis helps resolve some long-standing controversies in the field. First, Trem2+ foamy macrophages are not proinflammatory but interferon-inducible cell and inflammatory macrophages are. Second, about half of all foam cells are smooth muscle cell-derived, retaining smooth muscle cell
Contradicts
TREM2 in the pathogenesis of AD: a lipid metabolism regulator and potential metabolic therapeutic target.
Abstract
Triggering receptor expressed on myeloid cells 2 (TREM2) is a single-pass transmembrane immune receptor that is mainly expressed on microglia in the brain and macrophages in the periphery. Recent studies have identified TREM2 as a risk factor for Alzheimer's disease (AD). Increasing evidence has shown that TREM2 can affect lipid metabolism both in the central nervous system (CNS) and in the periphery. In the CNS, TREM2 affects the metabolism of cholesterol, myelin, and phospholipids and promotes the transition of microglia into a disease-associated phenotype. In the periphery, TREM2 influences lipid metabolism by regulating the onset and progression of obesity and its complications, such as hypercholesterolemia, atherosclerosis, and nonalcoholic fatty liver disease. All these altered lipid metabolism processes could influence the pathogenesis of AD through several means, including affecting inflammation, insulin resistance, and AD pathologies. Herein, we will discuss a potential pathway that TREM2 mediates lipid metabolism to influence the pathogenesis of AD in both the CNS and periphery. Moreover, we discuss the possibility that TREM2 may be a key factor that links central and peripheral lipid metabolism under disease conditions, including AD. This link may be due to impacts on the integrity of the blood-brain barrier, and we introduce potential pathways by which TREM2 affects the blood-brain barrier. Moreover, we discuss the role of lipids in TREM2-associated treatments for
Contradicts
Implementation and validation of single-cell genomics experiments in neuroscience.
Abstract
Single-cell or single-nucleus transcriptomics is a powerful tool for identifying cell types and cell states. However, hypotheses derived from these assays, including gene expression information, require validation, and their functional relevance needs to be established. The choice of validation depends on numerous factors. Here, we present types of orthogonal and functional validation experiment to strengthen preliminary findings obtained using single-cell and single-nucleus transcriptomics as well as the challenges and limitations of these approaches.
Contradicts
Alzheimer's Disease as a Disorder of Neuroimmune Dysregulation.
Abstract
Alzheimer's disease (AD) is traditionally defined by Amyloid-β (Aβ) plaques and tau neurofibrillary tangles, yet these proteinopathies alone fail to explain disease heterogeneity, progression, and cognitive decline. Emerging evidence identifies chronic neuroinflammation as a central integrator that converts molecular pathology into synaptic failure and neurodegeneration. In this context, Aβ acts as a danger-associated molecular pattern that activates microglial and astrocytic immune programs through receptors such as TREM2, TLRs, and RAGE, leading to inflammasome activation, cytokine release, and oxidative stress. These responses pathologically re-engage developmental complement pathways (C1q-C3-CR3), driving excessive synaptic pruning that correlates more closely with cognitive impairment than neuronal loss. Reactive astrocytes further amplify dysfunction by impairing glutamate and potassium homeostasis, promoting excitotoxic and metabolic stress, while inflammatory glia facilitate prion-like tau propagation via extracellular vesicles. Concurrent neurovascular inflammation disrupts blood-brain barrier integrity and cerebral perfusion, reinforcing immune-metabolic failure. Importantly, neuroinflammatory biomarkers (GFAP, sTREM2, YKL-40, cytokines, complement, and TSPO-PET) provide dynamic readouts of disease activity and therapeutic response. Together, these findings position AD as a disorder of failed immune resolution and support precision immunomodulatory and pro-resolving
Contradicts
Serum miRNA-155 and TREM2 as Non-Invasive Biomarkers for Monitoring Neuroinflammation and Disease Activity in Multiple Sclerosis.
Abstract
Serum miRNA-155 and TREM2 levels were investigated as potential non-invasive indicators. In this case-control study, serum miRNA-155 and TREM2 levels were evaluated in 80 patients with multiple sclerosis (MS) and 80 age- and sex-matched healthy controls. Levels were measured using qPCR and ELISA, with correlations assessed against Expanded Disability Status Scale (EDSS) scores, MRI lesion burden, and cerebrospinal fluid (CSF) markers (oligoclonal bands and immunoglobulin G index). Participants were followed for 24 months to evaluate biomarker dynamics during relapses and treatment. Patients with MS showed significantly elevated miRNA-155 and TREM2 levels compared to controls. Compared to healthy controls, the combined panel demonstrated good discriminatory performance (AUC = 0.924), with 89.0% sensitivity and 87.5% specificity. However, these metrics represent differentiation from health rather than disease specificity, as the study lacked disease control groups with inflammatory or non-inflammatory neurological disorders-a critical limitation for assessing actual diagnostic utility, performing better than the individual markers. Both biomarkers correlated moderately with EDSS (miRNA-155 r = 0.62, 95% CI 0.49-0.73; TREM2 r = 0.59, 95% CI 0.45-0.71), MRI abnormalities, and CSF parameters (r = 0.48-0.60, p < 0.001). Longitudinally, elevations tracked relapse activity, while therapy responders showed reductions (miRNA-155: -18.7%; TREM2: -15.3%), underscoring utility in monitori
Contradicts
Unraveling Parkinson's disease: The mystery of mitochondria and the role of aging.
Abstract
Parkinson's disease (PD) is a complex neurodegenerative disorder that poses significant burden on patients and families. Its exact cause is unknown, resulting in limited effective treatments. Mitochondrial dysfunction, linked to genetics, aging, oxidative stress, and environmental factors, is central to PD. Healthy elderly individuals have a compensatory mitochondrial DNA (mtDNA) mechanism in brain cells, but this mechanism is impaired in PD patients, leading to mtDNA reduction, respiratory chain dysfunction, decreased adenosine triphosphate (ATP) synthesis, and inadequate neuron energy. Aging increases oxidative stress, impairing mitochondrial function. Mitochondrial dysfunction in the dopaminergic neurons of the substantia nigra causes neuronal loss and disease progression. Aging microglia also play a crucial role, with a reduced capacity to clear neurotoxic substances, especially in the substantia nigra. A decrease in triggering receptor expressed on myeloid cells 2 (TREM2) gene expression shifts microglia to a pro-inflammatory phenotype, exacerbating neuroinflammatory responses and protein deposition. Down-regulation of the C-X3-C motif chemokine ligand 1 (CX3CL1)/C-X3-C chemokine receptor 1 (CX3CR1) signaling pathway increases the expression of pro-inflammatory cytokines, accelerating neuronal loss and disease progression. Recent research has identified a new astrocyte aging regulatory mechanism involving the cyclic GMP‒AMP synthase (cGAS)/stimulator of interferon genes
📖 Linked Papers (30)Export BibTeX ↗
TREM2 deficiency delays postnatal microglial maturation and synaptic pruning, leading to anxiety-like behaviors.
J Alzheimers Dis (2026) · PubMed:41930604 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Increased plasma soluble TREM2 levels in non-Alzheimer's dementia.
Acta neurologica Belgica (2026) · PubMed:41920402 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Molecular mechanism of Alzheimer's disease using integrated multi-omics.
Frontiers in aging neuroscience (2026) · PubMed:41907842 ↗
3 figures
Figure 1
No caption available
Figure 1
Schematic illustration of metabolic changes in neurons, astrocytes, and microglia in. Key associated genes include SLC2A1, G6PD in neuronal glucose and OXPHOS d...
The microglial TREM2 receptor programs hippocampal development in a mouse model of childhood deprivation.
Brain, behavior, and immunity (2026) · PubMed:41887542 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Emerging pathological mechanisms of Alzheimer's disease pathogenesis: from neuroimmune interactions to intercellular communication.
Frontiers in aging neuroscience (2026) · PubMed:41858793 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Alzheimer's Disease as a Disorder of Neuroimmune Dysregulation.
Neurology international (2026) · PubMed:41745721 ↗
5 figures
Figure 1
Neuroinflammatory axes driving Alzheimer’s disease pathology. This schematic summarizes five interconnected axes of neuroinflammation that contribute to the ini...
Figure 2
Amyloid-β as a danger signal driving neuroinflammation in Alzheimer’s disease. Oligomeric and fibrillar amyloid-β (Aβ) act as damage-associated molecular patter...
Plant-derived bioactive compounds modulate the gut microbiota in Alzheimer's disease: Metabolite signaling, neuroimmune circuits, and systems-level regulation.
Phytomedicine (2026) · PubMed:41678917 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Microglial metabolic reprogramming in Alzheimer's disease: Pathways, mechanisms, and therapeutic implications.
Ageing Res Rev (2026) · PubMed:41651180 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Loss of Triggering Receptor Expressed on Myeloid Cells 2 Impairs Microglial Function and Exacerbates Retinal Neurodegeneration in Glaucoma.
Am J Pathol (2026) · PubMed:41643896 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
AI-guided design of cyclic peptide binders targeting TREM2 using CycleRFdiffusion and experimental validation.
Bioorg Med Chem Lett (2026) · PubMed:41435973 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
The cholesterol 24-hydroxylase CYP46A1 promotes α-synuclein pathology in Parkinson's disease.
PLoS biology (2025) · PubMed:39964974 ↗
9 figures
Fig 1
CYP46A1 and 24-OHC are up-regulated in PD patients and PD model mice.
Fig 2
α-Syn pathology and its spread are significantly reduced after CYP46A1 removal in vivo.
Implementation and validation of single-cell genomics experiments in neuroscience.
Nature neuroscience (2024) · PubMed:39627589 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
📙 Related Wiki Pages (15)
Epidemic Spreading Model of Tau Pathologmechanismoga-inhibition-taumechanismCTRL-LabscompanyTau ProteinproteinKyoto UniversityinstitutionGranulovacuolar Bodies: Neuronal DefensemechanismTotal Tau (t-Tau) - BiomarkerbiomarkerTau Pathology Astrocytes (TPA)cellPRX005entityNTS — NeurotensingeneTau-Seed Interception Using ConformationideaTau-PROTAC Heterobifunctional Degrader fideauniversity-of-rochesterinstitutionTREM2 — Triggering Receptor Expressed ongeneTREM2 Proteinprotein
🏥 Translation
🧬 3D Protein Structure — TREM2
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for TREM2 from GTEx v10.
💉 Clinical Trials (5)Relevance: 46%
0
Active
Active
0
Completed
Completed
701
Total Enrolled
Total Enrolled
PHASE2
Highest Phase
Highest Phase
UNKNOWN·NCT06188429 · Hua Wei
50 enrolled · 2023-11-20 · → 2024-03-31
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterized by social impairment, repetitive behaviors, and narrow interests. With advancements in diagnostic techniques, the prevalen
ASD
DSM-5
RECRUITING·NCT07402161 · IRCCS Policlinico S. Donato
250 enrolled · 2025-10-01 · → 2027-10-01
This study focuses on improving early detection of Alzheimer's disease (AD) in patients with subjective cognitive decline (SCD), a preclinical stage of cognitive impairment, in the context of emerging
Subjective Cognitive Decline (SCD) Subjective Cognitive Complaints (SCCs) Subjective Cognitive Impairment
COMPLETED·NCT06224920 · Ludwig-Maximilians - University of Munich
140 enrolled · 2017-01-01 · → 2024-01-01
The temporal sequence of microglial activation, changes in functional and structural connectivity and the progression of neurocognitive deficits has not been conclusively clarified. To date, there hav
Alzheimer Disease Corticobasal Syndrome
magnetic resonance imaging electroencephalography blood and CSF biomarker
RECRUITING·NCT07360925 · Institute for Clinical and Experimental Medicine
60 enrolled · 2023-06-01 · → 2028-07-01
Evaluation of pericoronary adipocyte gradient (PCAT) in relationship with local atherosclerotic changes in a patient undergoing heart transplantation.
Heart Failure Heart Transplantation
Heart transplantation for the final stage of heart failure
RECRUITING·NCT06274528 · Washington University School of Medicine
201 enrolled · 2024-03-11 · → 2029-03-11
The purpose of this study is to see if the sleep aid, lemborexant, can decrease the amount of amyloid-beta and tau in the blood. Amyloid-beta and tau are proteins involved in the disease process leadi
Alzheimer Disease
Lemborexant 10 mg Lemborexant 20mg Placebo
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for TREM2.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$1
Timeline
6.0 years
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▼ 2.1%
Volatility
Low
0.0145
Events (7d)
2
Price History
▲43.2%💾 Resource Usage
LLM Tokens
537,676
$1.6130
Total Cost
$1.6130
🧭 Related
🕸 Knowledge Subgraph (155 edges)Showing top 50 of 155 edges by weightCentered on TREM2
Top relations:co discussed (48)regulates (23)co associated with (21)prevents (8)associated with (8)therapeutic target (7)
🔍 Show all 50 edges across 19 relations
Activate TREM2 signaling pathways to reprogram microglia from tau-propagating phenotype to tau-clear (1)
Deploy selective small molecule inhibitors targeting the tau-binding domain of LRP1 to prevent cellu (1)
LRP1 modulates tau propagation (1)
TREM2 modulates tau propagation (1)
Target ESCRT-III complex components (CHMP4B, VPS4) to selectively reduce tau-containing extracellula (1)
activates (4)
associated with (2)
catalyzes (1)
causes (2)
inhibits (1)
investigated in (1)
mediates (1)
modulates (1)
prevents (4)
protects against (1)
regulates (18)
SNAP25→Synaptic Vesicle Tau Capture InhibitionVCP→VCP-Mediated Autophagy EnhancementCHMP4B→Extracellular Vesicle Biogenesis ModulationLRP1→LRP1-Dependent Tau Uptake DisruptionDNAJB1→incoming tau seeds
▸ Show 13 more
NLGN1→Trans-Synaptic Adhesion Molecule ModulationTREM2→TREM2-mediated microglial tau clearance enhancemenHSP90AA1→HSP90-Tau Disaggregation Complex Enhancementsynaptic vesicle cycling→tau releaseLRP1→neuronal Tau uptakeP2RX7→exosome_secretionLRP1→Tau PropagationNLGN1→Tau PropagationVCP→Tau PropagationCHMP4B→Tau PropagationTREM2→Tau PropagationSNAP25→Tau PropagationHSP90AA1→Tau Propagation
stabilizes (1)
targets (1)
therapeutic target (7)
Trans-Synaptic Adhesion Molecule Modulation→Alzheimer's DiseaseSynaptic Vesicle Tau Capture Inhibition→Alzheimer's DiseaseHSP90-Tau Disaggregation Complex Enhancement→Alzheimer's DiseaseVCP-Mediated Autophagy Enhancement→Alzheimer's DiseaseExtracellular Vesicle Biogenesis Modulation→Alzheimer's Disease
🗺️ KG Entities (118)
ADAM10AKTAPOEAPOE4APPAQP4Alzheimer diseaseAlzheimer's DiseaseAutophagy-lysosome pathwayBIN1C1QCD33CD81CD9CDK5CHMP4BCTSDCX3CR1DAP12DNAJB1DYNC1H1ERKEXTRACELLULAR TAUEndosomal sorting / vesicle traffickinExtracellular Vesicle Biogenesis ModulExtracellular VesiclesFSCN1HS3ST1HSP70HSP90HSP90-Tau Disaggregation Complex EnhanHSP90AA1LAMP1LAMP2LC3LDLRLRP1LRP1-Dependent Tau Uptake DisruptionMAPKMAPTMTORNLGN1Neuronal UptakeP2RX7PI3KPSD95RAB7SDA-2026-04-02-gap-tau-prop-2026040200SDC4SNAP25SORL1SQSTM1Synaptic ConnectivitySynaptic Vesicle Tau Capture InhibitioSynaptic function / plasticityTAUTAU AggregationTFEBTNFTREM2TREM2-mediated microglial tau clearancTau PropagationTau SpreadingTau aggregatesTau protein / microtubule-associated pTrans-Synaptic Adhesion Molecule ModulVAMP2VCPVCP-Mediated Autophagy EnhancementVGLUT1alzheimer_diseasealzheimer_s_diseaseanatomical spreading patternanterograde tau transportautophagy pathwaychmp4b_tau_interactiondiseases-corticobasal-syndromeexosome functionexosome packagingexosome_secretionextracellular tau clearanceextracellular tau speciesextracellular_vesicle_traffickingglymphatic flowhsp90aa1_tau_interactionincoming tau seedsintercellular tau transferlong-range tau disseminationlrp1_tau_interactionlysosomal biogenesislysosomal_degradationlysosomal_membranemicroglial tunneling nanotubesmicroglial_activationneurodegenerationneuronal Tau uptakenlgn1_tau_interactionpathological tauprion-like templatingprocessedprotein_aggregate_uptakesess_SDA-2026-04-04-gap-tau-prop-20260sess_SDA-2026-04-04-gap-tau-prop-20260snap25_tau_interactionsynaptic functionsynaptic vesicle cyclingtau degradationtau misfolding propagationtau propagationtau releasetau seedstau-containing exosome formationtau_internalizationtau_propagationtrans-synaptic tau transfertrem2_dap12_microglial_signalingtrem2_tau_interactionvcp_tau_interaction
🔗 Dependency Graph (10 upstream, 2 downstream)
Depends On
LRP1-Dependent Tau Uptake Disruptionbuilds_on (1.0)Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulatorsbuilds_on (1.0)Microglial Purinergic Reprogrammingbuilds_on (1.0)TREM2 Conformational Stabilizers for Synaptic Discriminationbuilds_on (1.0)Tau-Independent Microtubule Stabilization via MAP6 Enhancementbuilds_on (1.0)SASP-Mediated Complement Cascade Amplificationbuilds_on (0.8)Noradrenergic-Tau Propagation Blockadebuilds_on (0.6)Purinergic P2Y12 Inverse Agonist Therapybuilds_on (0.6)Senescent Microglia Resolution via Maresins-Senolytics Combinationbuilds_on (0.6)Cell-Type Specific TREM2 Upregulation in DAM Microgliarefines (0.5)🧪 Adjacent Hypotheses10 siblings from the same analysis
Extracellular Vesicle Biogenesis Modulation
0.81CHMP4B · neurodegeneration · validated
LRP1-Dependent Tau Uptake Disruption
0.81LRP1 · neurodegeneration · validated
VCP-Mediated Autophagy Enhancement
0.79VCP · neurodegeneration · proposed
TREM2-mediated microglial tau clearance enhancement
0.78TREM2 · neurodegeneration · proposed
HSP90-Tau Disaggregation Complex Enhancement
0.63HSP90AA1 · neurodegeneration · proposed
LRP1-Dependent Tau Uptake Disruption
0.60LRP1 · alzheimers · archived
VCP-Mediated Autophagy Enhancement
0.59VCP · alzheimers · archived
Extracellular Vesicle Biogenesis Modulation
0.58CHMP4B · alzheimers · archived
Synaptic Vesicle Tau Capture Inhibition
0.58SNAP25 · alzheimers · archived
HSP90-Tau Disaggregation Complex Enhancement
0.57HSP90AA1 · alzheimers · archived
🗣 Debate PerspectivesGap Analysis | 4 rounds | 2026-04-12
Related Entities
▸Metadata
| status | proposed |
| _schema_version | 1 |
| hypothesis_type | None |
📊 Evidence Profile
Foundational
Evidence Balance
+0%
Certainty
100%
Debates
0
Incoming
4356
Outgoing
2236
0 supporting
0 contradicting
0 neutral
🌍 Provenance Graph
8 nodes, 14 edges
derives from (14)
hypothesis-h-b234254c→analysis-SDA-2026-04-02-gap-taanalysis-SDA-2026-04-02-gap-ta→hypothesis-h-4dd0d19bhypothesis-h-4dd0d19b→analysis-SDA-2026-04-02-gap-taanalysis-SDA-2026-04-02-gap-ta→hypothesis-h-b234254canalysis-SDA-2026-04-02-gap-ta→hypothesis-h-55ef81c5
▸ Show 9 more
hypothesis-h-55ef81c5→analysis-SDA-2026-04-02-gap-taanalysis-SDA-2026-04-02-gap-ta→hypothesis-h-18a0fcc6hypothesis-h-18a0fcc6→analysis-SDA-2026-04-02-gap-taanalysis-SDA-2026-04-02-gap-ta→hypothesis-h-0f00fd75hypothesis-h-0f00fd75→analysis-SDA-2026-04-02-gap-taanalysis-SDA-2026-04-02-gap-ta→hypothesis-h-73e29e3ahypothesis-h-73e29e3a→analysis-SDA-2026-04-02-gap-taanalysis-SDA-2026-04-02-gap-ta→hypothesis-h-fdaae8d9hypothesis-h-fdaae8d9→analysis-SDA-2026-04-02-gap-ta
🗣 Debate History2 sessions
gap_analysisInvestigate prion-like spreading of tau pathology through connected brain regions, focusing on trans-synaptic transfer, r4q=0.902026-04-12
This artifact has no version history yet.
Linked Artifacts (6572)
🧬 Related Hypotheses — same target / disease (20)
TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegeneration
Score: 0.892 · Target: TREM2 · neurodegeneration
TREM2-Mediated Microglial Dysfunction Disrupts Perivascular Tau Clearance
Score: 0.861 · Target: TREM2 · neuroscience
TREM2-Deficient Microglia as Drivers of Amyloid Plaque Toxicity in Alzheimer's Disease
Score: 0.847 · Target: TREM2 · neurodegeneration
Microglial Senescence Prevention via TREM2/SASP Axis
Score: 0.837 · Target: TREM2 · neurodegeneration
Microglial-Mediated Tau Clearance Dysfunction via TREM2 Signaling
Score: 0.827 · Target: TREM2 · neuroscience
TREM2-Dependent Switch Hypothesis: TREM2 Agonism Redirects SPP1 Signaling from Destructive
Score: 0.813 · Target: TREM2 · synaptic-biology
TREM2-APOE microglial state switching across AD, ALS, and PD
Score: 0.804 · Target: TREM2 · multi
Microglial TREM2-SYK Pathway Enhancement
Score: 0.798 · Target: TREM2 · neurodegeneration
TREM2-mediated microglial tau clearance enhancement
Score: 0.780 · Target: TREM2 · neurodegeneration
Enhancing Microglial Phagocytosis of Extracellular Tau via TREM2 Activation
Score: 0.771 · Target: TREM2 · neuroscience
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.761 · Target: TREM2 · alzheimers
sTREM2 as Biomarker of Cystatin-C Therapeutic Efficacy
Score: 0.757 · Target: TREM2 · neurodegeneration
Test: TREM2 enhances amyloid clearance
Score: 0.755 · Target: TREM2 · —
TREM2-SIRT1 Metabolic Senescence Circuit in Microglial Aging
Score: 0.744 · Target: TREM2 · neurodegeneration
APOE-TREM2 Interaction Modulation
Score: 0.741 · Target: TREM2 · neurodegeneration
Regional TREM2-Dependent Lipid Metabolism Determines Cortical Vulnerability in Alzheimer's
Score: 0.721 · Target: TREM2 · neuroinflammation
TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration
Score: 0.716 · Target: TREM2 · neurodegeneration
Test: TREM2 enhances amyloid clearance
Score: 0.712 · Target: TREM2 · —
Microglial TREM2 Activation Reduces Amyloid-Associated Neurotoxicity
Score: 0.710 · Target: TREM2 · neurodegeneration
TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegeneration
Score: 0.708 · Target: TREM2 · neurodegeneration
Reference URLs
Embed this artifact
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
HTML iframe
<iframe src="http://scidex.ai/artifact/hypothesis-h-b234254c?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
Markdown link
[TREM2-mediated microglial tau clearance enhancement](http://scidex.ai/artifact/hypothesis-h-b234254c)
Direct URL
http://scidex.ai/artifact/hypothesis-h-b234254c
Preview
🔄 Adjacent Artifacts
Recommended based on your interests
💬 Discussion
Loading comments...
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.